The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Hadji, Peyman; Stoetzer, Oliver; Decker, Thomas; Kurbacher, Christian M.; Marme, Frederik; Schneeweiss, Andreas; Mundhenke, Christoph; Distelrath, Andrea; Fasching, Peter A.; Lux, Michael P.; Lueftner, Diana; Janni, Wolfgang; Muth, Mathias; Kreuzeder, Julia; Quiering, Claudia; Grischke, Eva-Marie; Tesch, Hans

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Autor(en):

Hadji, Peyman; Stoetzer, Oliver; Decker, Thomas; Kurbacher, Christian M.; Marme, Frederik; Schneeweiss, Andreas; Mundhenke, Christoph; Distelrath, Andrea; Fasching, Peter A.; Lux, Michael P.; Lueftner, Diana; Janni, Wolfgang; Muth, Mathias; Kreuzeder, Julia; Quiering, Claudia; Grischke, Eva-Marie; Tesch, Hans

Tübinger Autor(en):

Grischke, Eva-Maria

Erschienen in:

Journal of Bone Oncology (2019), Bd. 14, Article UNSP 100199

Verlagsangabe:

Elsevier Science Bv

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.jbo.2018.09.010

ISSN:

2212-1374